Skip to main content

Table 2 Predictors of PRS

From: Visual quality assessment of the liver graft by the transplanting surgeon predicts postreperfusion syndrome after liver transplantation: a retrospective cohort study

 

univariable

multivariable

Wald

OR

95% CI

P

Wald

OR

95% CI

P

Donor related

 Age [years]

1.79

1.02

0.99–1.04

0.18

    

 Sodium [mmol/L]

3.92

1.05

1.00–1.10

0.048

3.74

1.06

1.0–1.13

0.053

 ALT [U/L]

0.94

1.00

0.99–1.00

0.76

    

 AST [U/L]

0.17

1.00

0.99–1.00

0.68

    

 Bilirubine [mg/dL]

0.28

0.92

0.68–1.24

0.60

    

 CIT [h]

4.09

1.19

1.05–1.41

0.04

1.62

1.14

0.93–1.38

0.20

 WIT [min]

3.54

1.05

0.99–1.11

0.06

    

 visual assessment by surgeona

        

  acceptable

11.03

13.14

2.87–60.03

0.001

9.21

12.23

2.43–61.59

0.002

  poor

6.27

14.6

1.79–118.9

0.01

5.34

13.40

1.48–121.1

0.02

 steatosis (histological)b

        

  stage 2

0.36

1.58

0.36–6.93

0.55

    

  stage 3

1.38

3.79

0.41–34.97

0.42

    

Recepient related

 labMELD

0.05

1.00

0.97–1.04

0.82

    

 PoHT

6.78

2.91

1.30–6.50

< 0.01

2.15

2.07

0.78–5.48

0.14

 NE dosage before reperfusion [0.1 μg kg−1 min−1]

7.86

2.00

1.23–3.24

0.01

7.56

2.20

1.26–3.86

0.01

  1. ALT alanine transferase, AST aspartate transferase, CIT cold ischemia time, WIT warm ischemia time, labMELD laboratory Model of end-stage liver disease score, PoHT portal hypertension, NE norepinephrine, OR odds ratio, CI confidence interval
  2. acompared to visual assessment category “good”; bcompared to stage 1
  3. Results of univariable (left) and multivariable (right) binary logistic regression analyses in 122 cases of LT to predict PRS. Only visually assessed steatosis by the surgeon prior to implantation and NE dosage before reperfusion remained significant predictors of PRS in the multivariable model